---
layout: default
title: Leveraging Large Language Models for Rare Disease Named Entity Recognition
---

# Leveraging Large Language Models for Rare Disease Named Entity Recognition

<div class="paper-toolbar">
  <a href="https://arxiv.org/abs/2508.09323" class="toolbar-btn" target="_blank">ğŸ“„ arXiv: 2508.09323v1</a>
  <a href="https://arxiv.org/pdf/2508.09323.pdf" class="toolbar-btn" target="_blank">ğŸ“¥ PDF</a>
  <button class="toolbar-btn favorite-btn" data-arxiv-id="2508.09323v1" data-paper-url="__CURRENT_PAGE__" onclick="toggleFavorite(this, '2508.09323v1', 'Leveraging Large Language Models for Rare Disease Named Entity Recognition')" title="æ·»åŠ åˆ°æ”¶è—å¤¹">â˜† æ”¶è—</button>
  <button class="toolbar-btn" onclick="copyLinkToClipboard(this)">ğŸ”— åˆ†äº«</button>
</div>


**ä½œè€…**: Nan Miles Xi, Yu Deng, Lin Wang

**åˆ†ç±»**: cs.CL, cs.AI

**å‘å¸ƒæ—¥æœŸ**: 2025-08-12

---

## ğŸ’¡ ä¸€å¥è¯è¦ç‚¹

**åˆ©ç”¨å¤§å‹è¯­è¨€æ¨¡å‹è§£å†³ç¨€æœ‰ç–¾ç—…å‘½åå®ä½“è¯†åˆ«é—®é¢˜**

ğŸ¯ **åŒ¹é…é¢†åŸŸ**: **æ”¯æŸ±ä¹ï¼šå…·èº«å¤§æ¨¡å‹ (Embodied Foundation Models)**

**å…³é”®è¯**: `å‘½åå®ä½“è¯†åˆ«` `ç¨€æœ‰ç–¾ç—…` `å¤§å‹è¯­è¨€æ¨¡å‹` `æç¤ºä¼˜åŒ–` `ç”Ÿç‰©åŒ»å­¦` `ä½èµ„æºå­¦ä¹ ` `æœºå™¨å­¦ä¹ `

## ğŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. ç¨€æœ‰ç–¾ç—…NERé¢ä¸´æ ‡æ³¨æ•°æ®ç¨€ç¼ºã€è¯­ä¹‰æ¨¡ç³Šå’Œé•¿å°¾åˆ†å¸ƒç­‰æŒ‘æˆ˜ï¼Œç°æœ‰æ–¹æ³•éš¾ä»¥æœ‰æ•ˆåº”å¯¹ã€‚
2. æœ¬ç ”ç©¶æå‡ºäº†ä¸€ç§ç»“æ„åŒ–æç¤ºæ¡†æ¶ï¼Œç»“åˆå¤šç§æç¤ºç­–ç•¥å’Œé¢†åŸŸçŸ¥è¯†ï¼Œæå‡NERæ€§èƒ½ã€‚
3. å®éªŒç»“æœæ˜¾ç¤ºï¼ŒGPT-4oåœ¨RareDisè¯­æ–™åº“ä¸Šè¶…è¶ŠBioClinicalBERTï¼Œä»»åŠ¡çº§å¾®è°ƒå®ç°äº†SOTAæ•ˆæœã€‚

## ğŸ“ æ‘˜è¦ï¼ˆä¸­æ–‡ï¼‰

ç¨€æœ‰ç–¾ç—…é¢†åŸŸçš„å‘½åå®ä½“è¯†åˆ«ï¼ˆNERï¼‰é¢ä¸´ç€æœ‰é™æ ‡æ³¨æ•°æ®ã€å®ä½“ç±»å‹ä¹‹é—´çš„è¯­ä¹‰æ¨¡ç³Šå’Œé•¿å°¾åˆ†å¸ƒç­‰ç‹¬ç‰¹æŒ‘æˆ˜ã€‚æœ¬ç ”ç©¶è¯„ä¼°äº†GPT-4oåœ¨ä½èµ„æºç¯å¢ƒä¸‹è¿›è¡Œç¨€æœ‰ç–¾ç—…NERçš„èƒ½åŠ›ï¼Œé‡‡ç”¨äº†é›¶-shotæç¤ºã€å°‘é‡ç¤ºä¾‹å­¦ä¹ ã€æ£€ç´¢å¢å¼ºç”Ÿæˆï¼ˆRAGï¼‰å’Œä»»åŠ¡çº§å¾®è°ƒç­‰å¤šç§åŸºäºæç¤ºçš„ç­–ç•¥ã€‚æˆ‘ä»¬è®¾è®¡äº†ä¸€ä¸ªç»“æ„åŒ–çš„æç¤ºæ¡†æ¶ï¼Œç¼–ç äº†é¢†åŸŸç‰¹å®šçŸ¥è¯†å’Œå››ç§å®ä½“ç±»å‹çš„æ¶ˆæ­§è§„åˆ™ã€‚å®éªŒç»“æœè¡¨æ˜ï¼ŒGPT-4oåœ¨RareDisè¯­æ–™åº“ä¸Šè¡¨ç°å‡ºç«äº‰åŠ›æˆ–ä¼˜è¶Šçš„æ€§èƒ½ï¼Œä»»åŠ¡çº§å¾®è°ƒå®ç°äº†æ–°çš„æœ€å…ˆè¿›ï¼ˆSOTAï¼‰ç»“æœã€‚

## ğŸ”¬ æ–¹æ³•è¯¦è§£

**é—®é¢˜å®šä¹‰**ï¼šæœ¬ç ”ç©¶æ—¨åœ¨è§£å†³ç¨€æœ‰ç–¾ç—…é¢†åŸŸå‘½åå®ä½“è¯†åˆ«ä¸­çš„æ•°æ®ç¨€ç¼ºå’Œè¯­ä¹‰æ¨¡ç³Šé—®é¢˜ã€‚ç°æœ‰æ–¹æ³•åœ¨å¤„ç†æœ‰é™æ ‡æ³¨æ•°æ®æ—¶è¡¨ç°ä¸ä½³ï¼Œéš¾ä»¥å‡†ç¡®è¯†åˆ«ä¸åŒç±»å‹çš„å®ä½“ã€‚

**æ ¸å¿ƒæ€è·¯**ï¼šè®ºæ–‡æå‡ºäº†ä¸€ç§åŸºäºå¤§å‹è¯­è¨€æ¨¡å‹çš„æç¤ºä¼˜åŒ–ç­–ç•¥ï¼Œé€šè¿‡ç»“æ„åŒ–æç¤ºæ¡†æ¶å¼•å…¥é¢†åŸŸçŸ¥è¯†å’Œæ¶ˆæ­§è§„åˆ™ï¼Œä»¥æé«˜NERçš„å‡†ç¡®æ€§å’Œæ•ˆç‡ã€‚

**æŠ€æœ¯æ¡†æ¶**ï¼šæ•´ä½“æ¶æ„åŒ…æ‹¬å¤šä¸ªæ¨¡å—ï¼šé¦–å…ˆæ˜¯æç¤ºç”Ÿæˆæ¨¡å—ï¼Œåˆ©ç”¨é›¶-shotå’Œfew-shotç­–ç•¥ï¼›å…¶æ¬¡æ˜¯æ£€ç´¢å¢å¼ºç”Ÿæˆï¼ˆRAGï¼‰æ¨¡å—ï¼Œæœ€åæ˜¯ä»»åŠ¡çº§å¾®è°ƒæ¨¡å—ï¼Œé’ˆå¯¹ç‰¹å®šä»»åŠ¡è¿›è¡Œä¼˜åŒ–ã€‚

**å…³é”®åˆ›æ–°**ï¼šæœ€é‡è¦çš„åˆ›æ–°åœ¨äºè®¾è®¡äº†ç»“æ„åŒ–æç¤ºæ¡†æ¶å’Œè¯­ä¹‰å¼•å¯¼çš„few-shotç¤ºä¾‹é€‰æ‹©æ–¹æ³•ï¼Œæ˜¾è‘—æå‡äº†æ¨¡å‹åœ¨ä½èµ„æºç¯å¢ƒä¸‹çš„è¡¨ç°ï¼Œä¸ä¼ ç»Ÿç›‘ç£æ¨¡å‹ç›¸æ¯”å…·æœ‰æ›´å¥½çš„å¯æ‰©å±•æ€§ã€‚

**å…³é”®è®¾è®¡**ï¼šåœ¨å‚æ•°è®¾ç½®ä¸Šï¼Œé‡‡ç”¨äº†é€‚åº”æ€§å­¦ä¹ ç‡å’Œç‰¹å®šçš„æŸå¤±å‡½æ•°ï¼Œç½‘ç»œç»“æ„ä¸Šç»“åˆäº†Transformeræ¶æ„ï¼Œç¡®ä¿äº†æ¨¡å‹åœ¨å¤„ç†å¤æ‚è¯­ä¹‰æ—¶çš„çµæ´»æ€§å’Œå‡†ç¡®æ€§ã€‚

## ğŸ“Š å®éªŒäº®ç‚¹

å®éªŒç»“æœè¡¨æ˜ï¼ŒGPT-4oåœ¨RareDisè¯­æ–™åº“ä¸Šçš„è¡¨ç°è¶…è¶Šäº†BioClinicalBERTï¼Œä»»åŠ¡çº§å¾®è°ƒå®ç°äº†æ–°çš„æœ€å…ˆè¿›ï¼ˆSOTAï¼‰ç»“æœã€‚æ­¤å¤–ï¼Œå°‘é‡ç¤ºä¾‹æç¤ºç­–ç•¥åœ¨ä½æ ‡è®°é¢„ç®—ä¸‹æä¾›äº†é«˜å›æŠ¥ï¼Œè€ŒRAGçš„è¾¹é™…æ”¶ç›Šç›¸å¯¹è¾ƒå°ã€‚

## ğŸ¯ åº”ç”¨åœºæ™¯

è¯¥ç ”ç©¶çš„æ½œåœ¨åº”ç”¨é¢†åŸŸåŒ…æ‹¬åŒ»ç–—æ–‡æœ¬åˆ†æã€ç”µå­å¥åº·è®°å½•ä¸­çš„ä¿¡æ¯æå–ä»¥åŠç¨€æœ‰ç–¾ç—…çš„ç ”ç©¶ä¸è¯Šæ–­ã€‚é€šè¿‡æä¾›é«˜æ•ˆçš„NERå·¥å…·ï¼Œèƒ½å¤Ÿå¸®åŠ©ç ”ç©¶äººå‘˜å’Œä¸´åºŠåŒ»ç”Ÿæ›´å¥½åœ°è¯†åˆ«å’Œç†è§£ç¨€æœ‰ç–¾ç—…ç›¸å…³ä¿¡æ¯ï¼Œæ¨åŠ¨ç›¸å…³é¢†åŸŸçš„å‘å±•ã€‚

## ğŸ“„ æ‘˜è¦ï¼ˆåŸæ–‡ï¼‰

> Named Entity Recognition (NER) in the rare disease domain poses unique challenges due to limited labeled data, semantic ambiguity between entity types, and long-tail distributions. In this study, we evaluate the capabilities of GPT-4o for rare disease NER under low-resource settings, using a range of prompt-based strategies including zero-shot prompting, few-shot in-context learning, retrieval-augmented generation (RAG), and task-level fine-tuning. We design a structured prompting framework that encodes domain-specific knowledge and disambiguation rules for four entity types. We further introduce two semantically guided few-shot example selection methods to improve in-context performance while reducing labeling effort. Experiments on the RareDis Corpus show that GPT-4o achieves competitive or superior performance compared to BioClinicalBERT, with task-level fine-tuning yielding new state-of-the-art (SOTA) results. Cost-performance analysis reveals that few-shot prompting delivers high returns at low token budgets, while RAG offers marginal additional benefit. An error taxonomy highlights common failure modes such as boundary drift and type confusion, suggesting opportunities for post-processing and hybrid refinement. Our results demonstrate that prompt-optimized LLMs can serve as effective, scalable alternatives to traditional supervised models in biomedical NER, particularly in rare disease applications where annotated data is scarce.

